

Longitudinal analysis within one hospital in sub-Saharan Africa over 20 years reveals repeated replacements of dominant clones of *Klebsiella pneumoniae* and stresses the importance to include temporal patterns for vaccine design considerations

*Eva Heinz^{1,2}, Oliver Pearse^{2,3}, Allan Zuza³, Sithembile Bilima³, Chisomo Msefula⁴, Patrick Musicha^{2,3}, Patriciah Siyabu⁵, Edith Tewesa⁵, Fabrice E Graf², Rebecca Lester^{3,6}, Samantha Lissauer^{3,7}, Jennifer Cornick^{3,7}, Joseph M Lewis^{2,3,7}, Kondwani Kawaza^{3,4}, Nicholas R Thomson^{8,9}, *Nicholas A Feasey^{2,3,10}

1. Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK
2. Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
3. Malawi Liverpool Wellcome Programme, Kamuzu University of Health Sciences, Blantyre, Malawi
4. Kamuzu University of Health Sciences, Blantyre, Malawi
5. Queen Elizabeth Central Hospital, Blantyre, Malawi
6. Division of Infection & Immunity, University College London, UK
7. Department of Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, UK
8. Parasites and Microbes Program, Wellcome Sanger Institute, Hinxton, UK
9. London School of Hygiene and Tropical Medicine, London, UK
10. School of Medicine, St Andrews University, UK

*Contact: eva.heinz@lstmed.ac.uk, Nicholas.feasey@lstmed.ac.uk

Keywords: AMR, Malawi, genome surveillance, healthcare-associated, nosocomial infections, surface antigens, neonatal infection, sepsis, capsular polysaccharide, ESKAPE

1 **Abstract**

2 Infections caused by multidrug-resistant gram-negative bacteria present a severe threat to
3 global public health. The WHO defines drug-resistant *Klebsiella pneumoniae* as a priority
4 pathogen for which alternative treatments are needed given the limited treatment options and
5 the rapid acquisition of novel resistance mechanisms by this species. Longitudinal
6 descriptions of genomic epidemiology of *Klebsiella pneumoniae* can inform management
7 strategies but data from sub-Saharan Africa are lacking.

8 We present a longitudinal analysis of all invasive *K. pneumoniae* isolates from a single
9 hospital in Blantyre, Malawi, southern Africa, from 1998-2020, combining clinical data with
10 genome sequence analysis of the isolates. We show that after a dramatic increase in the
11 number of infections from 2016 *K. pneumoniae* becomes hyperendemic, driven by an increase
12 in neonatal infections. Genomic data show repeated waves of clonal expansion of different,
13 often ward-restricted, lineages, suggestive of hospital associated transmission. We describe
14 temporal trends in resistance and surface antigens, of relevance for vaccine development.

15 Our data highlight a clear need for new interventions to prevent rather than treat *K.*
16 *pneumoniae* infections in our setting. Whilst one option may be a vaccine, the majority of
17 cases could be avoided by an increased focus on and investment in infection prevention and
18 control measures, which would reduce all healthcare associated infections and not just one.

19
20
21
22

23 Background

24 The burden of deaths in children under the age of five, including those due to neonatal sepsis,
25 is especially high in low- and middle-income countries (LMICs)(1); and one of the main
26 pathogens causing these is *Klebsiella pneumoniae* (*Kpn*)(2). Until the last decade, *Kpn* was
27 typically readily treatable with beta-lactam antimicrobials, in particular third generation
28 cephalosporins (3GC). The effectiveness of 3GC is lost when these bacteria acquire
29 extended-spectrum beta-lactamase enzymes (ESBLs). For *Kpn* there has been a drastic
30 increase in 3GC-resistance by acquisition of ESBL enzyme-encoding plasmids; the proportion
31 of *Kpn* hospital isolates that are ESBL-producing increased from 12% to >90% in parts of sub-
32 Saharan Africa (sSA) in the last decade(3). The main remaining treatment option are
33 carbapenems; these however are uncommonly available in sSA, rendering *Kpn* effectively
34 untreatable in large parts of Africa. This is particularly problematic for neonatal sepsis caused
35 by *Kpn*, and there is increasing evidence from large studies such as BARNARDS(2) and
36 CHAMPS(4) that the burden of disease caused by *Kpn* falls most heavily on this patient group.
37 Treatment options for neonates are even more limited than for other age groups as therapy
38 needs to be intravenous and some antimicrobial classes are contraindicated, however delay
39 in establishing appropriate therapy is even more dangerous.

40
41 The population structure of *Kpn*, similar to other opportunistic pathogens that thrive in the
42 environment, is highly complex(5). Understanding long-term population trends of clinically
43 relevant lineages at both a local and global scale, and which antimicrobial resistance plasmids
44 and elements they encode, is potentially relevant to guiding treatment, infection prevention
45 strategies and vaccine development. However, few longitudinal studies of *Kpn* population
46 have been published so far, and the majority have come from collections established in high-
47 income settings or South East Asia(6–10), whilst data from Africa and South America remain
48 sparse. Low-income countries in sub-Saharan Africa are particularly underrepresented in
49 'global' collections of pathogen genome data, despite often carrying the highest burden of
50 disease(2).

51
52 Whilst *Kpn* has a global distribution, there are clear geographical concentrations of dominant
53 lineages and resistance genes, likely reflecting local antimicrobial pressure, patient
54 populations, and a range of other determinants. Developing a more representative picture of
55 the global epidemiology of *Kpn* is relevant to the development of vaccines targeting *Kpn*, to
56 ensure that the lineages and associated LPS O-antigens and capsular polysaccharide
57 antigens most prevalent in countries with the highest burden of disease are targeted. A better
58 understanding of the genomic epidemiology of *Kpn* in low-income countries is also crucial to
59 advocate for access to antimicrobials, in particular newer agents, which is often profoundly
60 limited by cost, leaving isolates that can be readily treated in high- or middle-income countries
61 *de facto* untreatable. Further, knowing at a facility level where problematic hotspots of
62 transmission are within a hospital setting can help focus infection prevention and control (IPC)
63 efforts.

64
65 To address this urgent need for a better understanding of the *Kpn* population in sSA, we
66 performed whole-genome sequencing on all bloodstream isolates phenotypically identified as
67 *Kpn* from Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi, which has
68 undertaken sentinel surveillance of bacteraemia and meningitis in partnership with the Malawi-
69 Liverpool Wellcome Programme (MLW) since 1998(3). Our analyses include all isolates,
70 irrespective of resistance profile or patient demographic, from 1996 to 2020, with no change

71 in sampling strategy from 2000 - 2020. We report the shifts in resistance profile and population
72 structure over time and highlight the relevance to consider trends over time and not just total
73 numbers for considerations of new drug regimens or vaccine target selection.

74

75 **Results**

76 **The QECH bloodstream isolate collection**

77 QECH is the main referral hospital for the southern region of Malawi and the main hospital for
78 Blantyre, the second largest city of Malawi (population 800,024 at the 2018 census). It has
79 approximately 1,000 beds and receives around 10,000 adult medical and 30,000 paediatric
80 medical admissions per year. A quality assured diagnostic microbiology service was initially
81 implemented in partnership with MLW at QECH in 1998. Laboratory blood culture was initially
82 manual, and an automated system was implemented in 2000 (BacT/ALERT, Biomerieux). The
83 diagnostic microbiology service expanded to culture cerebrospinal fluid (CSF) from 2002.
84 During the study period, all adult and paediatric medical patients with suspected sepsis or
85 meningitis were eligible for blood and/or CSF culture at the discretion of the admitting
86 physician, and where possible before the administration of antimicrobials. Bacterial isolates
87 were identified by standard techniques detailed in the methods.

88

89 At the start of the period, first-line treatment against bloodstream infections was crystal-
90 penicillin and chloramphenicol although gentamicin was used in neonates instead of
91 chloramphenicol. This began to change with the introduction of the 3rd-generation
92 cephalosporin ceftriaxone from 2004, which was rapidly adopted as a first line agent by the
93 Department of [adult] Medicine and more slowly by the Department of Paediatrics, which
94 continues to use penicillin and gentamicin in the management of neonatal sepsis, as per WHO
95 guidelines(11).

96

97 Members of the order Enterobacterales including *Kpn* were identified by API biochemical
98 index (Biomerieux, France). *Klebsiella pneumoniae* is known to comprise a species complex
99 including *Klebsiella pneumoniae subsp. pneumoniae* as well as several closely related
100 species like *K. variicola* and *K. quasipneumoniae* and their respective subspecies(12). These
101 can only be identified to species complex level via API, and we therefore refer to all members
102 of the *K. pneumoniae* species complex as *Kpn* and specify when referring to specific
103 (sub)species (Fig 1A).

104

105 **Dramatic increase in *Kpn* cases from 2016**

106 The crude frequency of *Kpn* cases was high at the start of the period with 121 cases in 1998,
107 although this overlapped with a year of active surveillance of febrile adult patients(13) and we
108 thus focused longitudinal analyses from 2000 onwards. The number of cases from 2000 -
109 2015 was stable with a mean of 44 cases per year (Fig 1A). This increased to a mean of 187
110 cases per year from 2016-2021 with a peak of 279 in 2019.

111

112 Neonatal infection with *Kpn* accounted for 39.3% of all *Kpn* infections, even though only 11.2%
113 of all blood cultures were taken from this patient group. The overall rate of *Kpn* isolation was
114 24.9 per 1000 blood cultures for neonates, 4.3 per 1000 blood cultures for other patients (rate
115 ratio of neonates vs non-neonates 5.11 [95% CI 4.66 - 5.61]). The increase in *Kpn* cases post
116 2016 was driven by an increase in neonatal infections (Fig S1A-1G); there were peaks in the
117 *Kpn* blood culture isolation rate in neonates in 2008, 2014 and 2017 which suggest outbreaks
118 or ongoing transmission on the neonatal unit (Fig 1B), and our genomic analyses further

119 support hospital transmission given the close genetic relationships of the respective isolates.
120 Though the blood culture positivity rate was increased for most age groups in the period from
121 2016-2021, for neonates this increase was particularly marked (33.5 per 1000 blood cultures
122 in the period 2016-2021 compared to 15.4 per 1000 blood cultures in the period 1998-2015;
123 Fig S1A-1D). As well as the peak in neonatal cases, there was also a much smaller peak in
124 the adult age group, which shifted from the 30-35 year age group in the period from 1998-
125 2015 to the 35-40 year age group in the period from 2016-2021 (Fig S1E-1H).

126 127 **Increase in *Kpn* numbers driven by temporally defined expansions of sequence types** 128 **(STs)**

129 We retrieved 1313 isolates not previously sequenced from the QECH *Kpn* collection, 1302 of
130 which could be recovered for growth and yielded enough DNA for sequencing; and 1156 of
131 these passed all quality control steps for further analysis (details see methods; Fig S2). In
132 addition, we included 217 samples from previously published studies of this collection(14–16),
133 resulting in 1373 sequenced genomes analysed in this study (Fig 1C).

134
135 The majority (1274/1373, 92.8%) belong to *Klebsiella pneumoniae* subsp. *pneumoniae* with
136 only very small proportions representing other (sub)species, including *K. quasipneumoniae*
137 subsp. *quasipneumoniae* (10/1373, 0.7%), *K. quasipneumoniae* subsp. *simillipneumoniae*
138 (46/1373, 3.4%) and *K. variicola* subsp. *variicola* (43/1373, 3.1%). Based on phenotypic
139 microbiology data (Fig 1A and 1B) we observed a drastic increase in isolates from neonatal
140 infection in 2016/2017 which is reflected in our sequenced collection.

141
142 Assessing diversity of STs over time highlights that the increase in *Kpn* infections represents
143 repeated increase and subsequent decrease in numbers of different multilocus sequence
144 types (Fig 2A). Whilst the earlier years show a diverse composition of STs with small numbers
145 of each ($n < 15$ total), the increase in total *Kpn* numbers is mainly driven by one or two major
146 STs, with these peaks spanning approximately 1.5 to 2 years each. We furthermore observe
147 that after the increase of isolates of the major STs, each of them reverts to their original very
148 low numbers (Fig 2A).

149
150 A previous study(15) highlighted an outbreak of ST340 across the neonatal unit which is
151 reflected here, where it comprises 31 out of 105 isolates in 2013 & 2014 (29.5%; Fig 2A). We
152 then see an increase of the numbers of ST14 (19 / 44 in 2015; 43.2%) which is present at a
153 lower proportion before and after this period; followed by an increase in ST25 (13 / 87 in 2016;
154 14.9%) which again is present at lower proportions before and after. The year 2017 then saw
155 a steep increase in *Kpn* infections overall; mainly driven by an expansion of ST39 which
156 comprises more than half the samples at the time (100/188 in 2017; 53.2%). This clone
157 however again retreats back to low numbers, with a few lineages dominating, in particular
158 ST1552 (35 / 208 in 2018; 16.8%) and ST35 (40 / 208 in 2018; 19.2%). The year 2019 then
159 sees another increase in ST14 (61 / 236 in 2019; 25.8%) as well as ST15 (30 / 236 in 2019;
160 12.7%), which is a known high-risk clone predominantly found in South East Asian collections
161 where it has been linked to an early spread of carbapenem resistances via *bla_{NDM}*
162 genes(17,18).

163
164 **Isolation of *Kpn* from neonatal and paediatric wards account for observed changes,**
165 **whilst adult infections remain stable over time**

166 The patterns over time differ significantly between wards (Fig 2B), suggesting the increase in
167 *Kpn* infections could represent a pattern of repeated ward-specific outbreaks, rather than a
168 generalised increase across all wards (Fig 2B). This pattern of ward-focused increases in
169 isolate numbers was repeatedly observed on the Chatinkha neonatal unit and the surgical
170 PICU/HDU, where most of the changes in numbers of isolates occur. An indication of local
171 outbreaks is further supported by analysing the major STs, which increase at defined times in
172 specific wards (Fig 2B and 2C; Fig S3). To investigate the impact of closely related isolates
173 (<5 core SNP distance) that are likely within-hospital transmissions on the number of infections
174 overall, we analysed a core genome tree for each of the three species and identified closest-
175 neighbour SNP distances in a root-to-tip approach(19) (Fig 3). This highlighted that most
176 highly clonal lineages (defined as <5 SNPs) are derived from *K. pneumoniae* subsp.
177 *pneumoniae* (Fig 3A) representing 402 of 1165 isolates as a conservative estimate based on
178 whole-species analyses, with 43% of the *K. quasipneumoniae* subsp. *similipneumoniae* (20
179 of the 46 isolates in 6 lineages, Fig 3B) and 25% of the *K. variicola* isolates (10 of the 40
180 isolates of this species, Fig 3C); and no <5 SNP related isolates of *K. quasipneumoniae* subsp.
181 *quasipneumoniae*.

182
183 Despite removing the single-isolate STs for this analysis, our dataset still contains a high
184 number of *K. pneumoniae* subsp. *pneumoniae* STs, which results in a highly diverse dataset.
185 As this diversity has potential to impact on tree resolution depending on reference used(20),
186 we investigated three key STs in more detail. We focused on ST35, ST39, and the closely
187 related ST14 and 15 together, whose pattern of accumulation in a ward and year strongly
188 indicates multiple hospital-associated transmissions (Fig S3), in more detail by mapping
189 against strain-specific reference genomes (Fig 3A). ST39 and ST35 are two key STs when
190 considering the per-year breakdown of isolates per ward for the neonatal unit (Chatinka; Fig
191 S3); whilst ST14 and ST15 were identified in high numbers in the PICU/HDU in the paediatric
192 surgical ward (Fig S3). Here, we can observe that 77% of the isolates (51/55 ST35, 110/136
193 ST39, 182/254 ST14-15) have their nearest neighbour within the threshold of 5 SNPs;
194 representing 100% (17/17) of ST35 and 88.9% (80/90) of ST39 from Chatinka and 88%
195 (57/65) ST14 and 15 from the PICU/HDU (Fig 3A). This high relatedness of isolates strongly
196 supports within ward transmission and the argument that *Kpn* is a healthcare associated
197 cause of neonatal sepsis. As patients are regularly transferred from Chatinka to the
198 PICU/HDU if surgical procedure is required, these wards are furthermore already linked by a
199 clear transmission path via patients, and several potential between-ward transmission events
200 are indicated in particular in ST35 and ST14/15 (Fig 3D, F).

201
202 Over the period from 2015-2018 there was an increased focus on performing blood cultures
203 to ensure every neonate on Chatinka nursery that met the clinical criteria for suspected
204 neonatal sepsis was included, which may explain some of the large increase in *Kpn* cases in
205 2017 on the nursery. Establishing optimal IPC has been an ongoing challenge(21);
206 specifically, handwashing has been difficult due to intermittent water supply and a lack of
207 access to soap or hand sanitiser and there are limited numbers of cots, so neonates have
208 often shared them. In response to the large increase in *Kpn* cases there was renewed focus
209 on IPC; hand sanitizer and soap procurement was prioritized, deep cleans of the ward
210 environment were performed regularly, there was increased cleaning of ward surfaces, ward
211 traffic was limited, wooden cots are being replaced with easier to clean plastic ones, the
212 number of neonates sharing a cot was reduced and oxygen delivery devices are being
213 replaced with single use items.

214

215 **Antimicrobial resistance and implications for treatment**

216 Phenotypic resistance profiles of the strains, where available, mirrors the very concerning
217 trends reported previously for *Kpn* in QECH(3) (Fig S4, Table S4). Resistance against the
218 frontline treatments is widespread; a particular concern is a high proportion of isolates with
219 ceftriaxone, gentamicin and cotrimoxazole resistance from 2012 onwards with very little
220 change over time (Fig S4A-C; >75% of tested isolates were resistant to these agents each
221 year 2012 – 2020). We notice some variation in co-amoxiclav (augmentin: amoxicillin +
222 clavulanic acid) susceptibility profiles but from 2019 again show >75% of tested isolates as
223 resistant (Fig S4A). Importantly, we notice that a trend of increased numbers of
224 chloramphenicol susceptible isolates (Fig 4B, Fig S4G), which has previously reported in
225 Malawi(3), is also explicit in our *Kpn* collection in particular in recent isolates (38.7%, 51.5%,
226 72.2% isolates sensitive for 2018-2020). Presence of *catA1* or *catA2* agree well with
227 phenotypic resistance whereas presence of *catB4* did not as shown in Fig 4B; where we see
228 a large number of isolates with sensitive phenotype, no *catA1/2* but *catB4*, whereas only a
229 small fraction of isolates has resistant phenotype, no *catA1/2* but *catB4* where we hypothesize
230 a different mechanism is likely driving the resistant phenotype. For isolates with resistant
231 phenotype and encoding both *catA1/2* and *catB4* the resistance is presumed to be driven by
232 *catA1/2*. This agrees with *catB4* representing a non-functional truncated variant of *catB3* as
233 was recently reported. We furthermore note a sensitivity of 50% or higher in the majority of
234 years measured in ciprofloxacin (6/9 years from 2012 to 2020, including 2017, 2018 and 2020;
235 Fig S4E, Table S4), which together with chloramphenicol thus represent two antimicrobials
236 that might thus be valid treatment options.

237

238 Resistance to 3GC was widespread (83% resistance to cefpodoxime/ceftriaxone by 2020; Fig
239 S4A) and almost exclusively driven by acquisition of the *bla*_{CTX-M-15} gene, which continuously
240 outcompetes other ESBL-encoding genes that are occasionally present in the *Kpn* population,
241 but which are only sporadically detected (Fig 4A, Table S2). The number of plasmid replicons
242 per isolate stabilised after the first increase in numbers around 2015, highlighting that a few
243 large AMR plasmids are likely responsible for the majority of AMR-isolates (Fig S5C, Fig S6A,
244 Table S3). Strains with a moderate number of plasmid replicons dominate the population (0-
245 5) and this remains stable over time, with only a small number of isolates with more than five
246 plasmid replicons associated that remains at similar numbers over time (Fig S6A). This
247 indicates that the change to a predominantly ESBL⁺ population was the key event, with the
248 population then remaining stable over time with respect to plasmid diversity and numbers of
249 resistance genes (Fig S6B).

250

251 Carbapenem resistance genes are still only rarely observed; we identified two samples
252 encoding for *bla*_{NDM-1}; one in a ST39 in 2016 and one in a ST45 in 2019, perhaps unsurprisingly
253 as carbapenem usage is still comparatively unusual. We also investigated resistances against
254 other potential alternative treatment options colistin, fosfomycin and tigecycline. Resistance
255 to these agents are all at low levels, with only one acquired fosfomycin resistance gene
256 detected (*fosA*) and none against colistin or tigecycline predicted in our dataset, and one
257 isolate with predicted mutations that can confer resistance to colistin (*pmrB*), indicating that
258 these might be viable alternatives for ESBL⁺ infections at QECH, although tigecycline is
259 contraindicated in children under 8y (Table S2) and neither agent may not be ideal treatments
260 for bacteraemia(22,23). Tigecycline resistance is often conferred by upregulation of transport
261 proteins and thus challenging to predict and has also been observed during within-patient

262 evolution(24–26); we could however not detect the described plasmid-derived antimicrobial
263 resistance genes *tetX* in our collection(27).

264

265 Based on AMR phenotype identified by disc diffusion, amikacin remains a viable alternative
266 to gentamicin, although there are concerns over blood brain barrier penetration in cases of
267 meningitis and renal toxicity in settings where therapeutic drug monitoring is not possible.
268 Phenotypic data are corroborated by a more detailed analysis of the aminoglycoside AMR
269 genes (Fig 4C and 4D). In total 90.5% of all isolates (1243/1373) are predicted to encode one
270 or more aminoglycoside resistance genes, however, the majority are predicted to confer
271 resistance to streptomycin (ANT3) and gentamicin (AAC(3)-II; ANT(2'')-I; Fig 4D). Only a
272 fraction of these strains (43.2%, 593/1373) encoded one of the genes predicted to confer
273 resistance against amikacin (AAC(6')-I; Fig 4C). Aminoglycoside resistance is known to be
274 challenging to predict(28); whilst phenotypic gentamicin resistance testing matches very well
275 with the predicted profile based on acquired genes, the presence of AAC(6')-I does not by
276 itself confer resistance in a large number of isolates, with only 12 isolates encoding for either
277 of these, representing 2%, actually showed a resistant phenotype (Fig 4D; Table S4).

278

279 **Potential vaccine target stability**

280 The *Kpn* polysaccharide antigens are of high interest as vaccine targets; in particular the large
281 capsular antigen. As expected, we observed a very high number of different K-loci (90
282 predicted), as well as a diverse set of O-loci (15 predicted), the latter are known to be far less
283 diverse in *Kpn*(29). Recent findings furthermore showed that *wbbZ*, encoded on the
284 chromosome outside the O-locus, contributes to the diversity of the O-Ag structure displayed
285 by *Kpn* and thus two isolates with the same O-locus can still result in different O-types based
286 on the presence or absence of this gene. Immunologically relevant differences in O-Ag thus
287 requires the prediction of the O-Ag locus and *wbbZ*(30), so we added this to our O-Ag type
288 predictions (Fig S7A-D) where we thus distinguish between O1a and O1b as described by
289 Kelly *et al*(30). Reflecting the trend observed with the ST types, we observe temporal variation
290 in prevalence of O-types and K-types (Fig 5A and 5D, Fig S7A). The non-ESBL population
291 again displays a much greater diversity for both types of antigen (Fig 5B and 5E, Fig S7B),
292 whilst the ESBL population is more biased towards dominant O- and K-types (Fig 5C and 5F,
293 Fig S7C).

294

295 Beyond the dominant O1b (821/1373; 59.8%) and O2afg (184/1373; 13.4%) predicted O-
296 antigen types, the infrequently observed type O4 comprises a substantial fraction of isolates
297 (90/1373; 6.6%); and 35 isolates have a prediction accuracy as “Low” or “None” which can
298 indicate either low assembly quality or novel O-Ag loci and types. In addition, we note two
299 isolates with unknown O-Ag locus encoding for additional *wbbY* and *wbbZ* genes, indicating
300 that more variation might be within possibly novel O-Ag loci depending on additional enzymes
301 encoded in the chromosomal backbone (Table S5). We furthermore note 8 isolates with
302 O1/O2 loci encoding for only *wbbZ* (not *wbbY*); whilst the recent work showed no structural
303 differences in the O-Ag if *wbbZ* alone was added, we cannot exclude other carbohydrate
304 enzymes on the chromosomes of our isolates that might lead to additional different structures
305 if combined with *wbbZ* (Table S5). Of relevance, we also observe variation of O- and K-type
306 combinations within the same sequence type (Fig 5G and H, Fig S7D) and with each other
307 (Fig 5I, Fig S7E).

308

309 Considering hypothetical vaccine strategies and constructs, an efficacious maternally
310 administered quadrivalent O-antigen based vaccine (O1a, O1b, O2afg, O4; including O1a as
311 O1b-encoding isolates can switch between O1a and O1b(30)) would be expected to protect
312 against up to 89% of cases of neonatal sepsis in Blantyre (345/388), whereas a K-antigen
313 based vaccine would require 22 K-antigens to be represented to protect against an equal
314 number of cases of neonatal sepsis when taking the entire timespan of our study into account
315 (KL10, KL102, KL103, KL104, KL106, KL108, KL117, KL142, KL15, KL16, KL17, KL19, KL2,
316 KL23, KL25, KL30, KL43, KL48, KL51, KL52, KL62, KL9); a quadrivalent K-antigen based
317 vaccine (KL2, KL25, KL30, KL102) would cover 58% (198/388) of cases. We furthermore
318 observe no regular cycling between a specific set of K-types, but rather that different K-types
319 regularly emerge associated with major clones (Fig 5). Given current knowledge of >180
320 predicted K-types(31) and >70 determined structures so far(32–34) (likely an
321 underestimation), and the propensity of the K-locus to recombine, it will be very challenging
322 to predict how long a K-type vaccine would remain effective.

323

324 **Trends of resistance vs virulence determinants**

325 Whilst most *Kpn* isolates are opportunistic pathogens with poorly understood virulence
326 profiles, the hypermuroid phenotype is a known virulence determinant arising from
327 hyperproduction of capsule and causing a different clinical infection type, i.e. liver abscess
328 and meningitis in otherwise healthy individuals, often progressing very rapidly and with poor
329 prognosis. The capsule hyperproduction is usually driven by acquisition of a virulence plasmid
330 encoding for the capsule polysaccharide upregulation factor *rmpA2* as well as several
331 siderophore systems (aerobactin, salmochelin, colistin) that enable iron scavenging. This
332 phenotype is of particular concern given the recent convergence of hypervirulent with
333 multidrug resistant isolates. Whilst we note hypervirulent isolates present (defined here as
334 kleborate virulence score >1, i.e. encoding virulence factors in addition to the often
335 chromosomal yersiniabactin) from the very early sampling times on in our collection (Fig
336 S8A,B, Fig S5B), these remain sporadic; in contrast to multidrug resistant isolates (Fig S8C,D
337 Fig which are absent at these early sampling times but rapidly become the majority of isolates
338 from 2007/8 onwards (Fig S8D). Whilst we note a total number of >10 isolates for both ST86
339 and ST268, two STs carrying the *rmpA2* gene and widely observed as hypervirulent
340 phenotypes, these occur in different years and wards, highlighting that hospital-derived
341 transmission is highly unlikely (Fig S8B). Whilst it is of concern that we observe some of these
342 potentially hypervirulent isolates (encoding for *rmpA2*) also encoding an ESBL gene (22 total;
343 9 of these ST86, no ST268) there seems to be no selective advantage; the first isolate carrying
344 this combination is observed in 2010 but a maximum of 4 isolates per year are observed until
345 2020. This small number of putative hypervirulent isolates is in accordance not only with
346 bloodstream isolates in general but also with a study comparing carriage with infectious
347 isolates from adults in Blantyre, where only a very small number of isolates encoding virulence
348 determinants were identified, all of them in infectious isolates(35,36).

349

350 **Discussion**

351 Neonatal sepsis is responsible for a high proportion of deaths in children under 5 in sSA, with
352 *Klebsiella* by now being both the most prevalent gram-negative pathogen and increasingly
353 hard to treat. We have analysed a longitudinal collection of routine diagnostics invasive
354 (bloodstream and CSF) isolates of *Kpn* spanning from 1998 – 2020, during which time AMR
355 increased drastically. We determined longitudinal patterns of patient demographics, *Kpn*
356 population trends, vaccine targets, resistance elements and remaining treatment options. This

357 exceptional resource, not only for sSA but also world-wide, enables us to understand the
358 dynamics of *Kpn* over an exceptionally long time scale where the sampling was not biased
359 towards resistance types. In particular, it allows us to see the dynamics before, during, and
360 after the significant expansion of ESBL producing *Kpn* at maximum resolution; and highlights
361 the need to consider not only major types based on total numbers but the temporal dynamics
362 of vaccine targets such as cell surface polysaccharides.

363
364 *Kpn* initially showed a bimodal age distribution in patients at QECH(3) and there were
365 concerns that increasing life expectancy would lead to a higher number of adult infections;
366 however, this trend has yet to be seen, and adult bloodstream infections were significantly
367 reduced overall following the widespread distribution of antiretroviral therapy(37). The stark
368 increase in infections from 2016 onwards is almost exclusively seen in neonates and children
369 where ward-restricted clonal expansions that are subsequently replaced with other successful
370 clones. This suggests that context appropriate, effective, scalable infection prevention and
371 control (IPC) targeted towards the most vulnerable patient groups in the hospital and a better
372 understanding of *Kpn* transmission routes and reservoirs would prevent a large proportion of
373 the cases caused by *Klebsiella* bloodstream infection. Such approaches have the potential to
374 protect vulnerable babies against all healthcare associated infections rather than just one
375 pathogen and are available now, unlike a vaccine strategy that will take years to develop and
376 implement without guarantee for success.

377
378 The main sequence types in our study were ST39, ST14 and ST15. While ST39 and ST14
379 are not necessarily the most prevalent ones observed globally, ST15 is widely reported in
380 SouthEast Asia causing clonal outbreaks whereas it showed a different pattern in our setting
381 driving smaller expansions but also as a lot of sporadic isolates occurring over time. This
382 highlights the need for more data from sSA to understand the complex diversity of this
383 organism in high-risk areas, as not only the ST composition, but also their patterns, differ
384 between settings. The two key insights we gain from the population pattern is that the lineages
385 continue to replace each other as the dominant clone over longer time periods, and that in our
386 setting, this expansion is mainly driven by an increase in cases in neonatal patients. Most of
387 the major sequence types are present at a steady, much lower proportion, before and after
388 their respective clonal expansions, emphasizing the relevance of understanding what leads to
389 the wave-like pattern of clonal expansions in *Kpn* populations.

390
391 This temporal variability also favours prioritisation of IPC strategies to prevent the introduction
392 of new lineages. It may be that increased IPC efforts in response to ward outbreaks contribute
393 to or are the single cause for the sudden stops of clonal expansions. We have little
394 understanding of the ability of *Kpn* to survive on abiotic surfaces, which represents one of the
395 key differences between HIC and LMIC settings, as the latter often use wooden furniture and
396 bristled plastic tubing due to limited resources, which might lead to different *Kpn* lineages
397 being successful. A similar question remains open regarding agents used for disinfection, as
398 resource-limited settings often rely on basic soap agents and use unsafe water, whilst HIC
399 routinely use industrially produced, quality controlled disinfectants.

400
401 Our data allow insight into AMR patterns in our setting. Ceftriaxone resistance, almost
402 exclusively due to the ESBL-encoding *bla*_{CTX-M-15}, is widespread. Whilst carbapenems are
403 rarely available and resistance is already emerging (38,39), several treatment options are still
404 viable, such as amikacin. Our analysis also emphasizes again that aminoglycoside resistance

405 is notoriously hard to predict and might be impacted by the genetic background (for example
406 efflux pumps) and not only acquired resistance genes, and should therefore at this stage not
407 be ruled out based on genomic data but confirmed via phenotyping. Most isolates were
408 phenotypically resistant to gentamicin; whether this is consequent on the predicted resistance
409 genes, or whether other mechanisms drive this resistance is important to determine to improve
410 the value of genotypic predictions for aminoglycosides. It will remain to be further investigated
411 whether this is due to other interfering genes or low expression of the resistance gene and
412 might be an indication of heteroresistance in the population which needs to be carefully
413 considered(40). We furthermore observe a trend in re-emergence of chloramphenicol
414 sensitivity, putatively in part driven by the spread of a non-functional CAT copy. Continuing to
415 monitor re-emergence of susceptibility to agents no longer in use is of high relevance to allow
416 timely re-introduction of drugs and can give us insights into the potential of rotating
417 antimicrobial regiments over longer time spans to allow sensitivity to re-emerge.

418

419 There was little resistance predicted and observed to colistin, a last-line treatment option, in
420 QECH *Kpn* isolates. Especially the lack of mobile resistance elements is encouraging, but
421 also stresses the urgent need for better management of animal health as colistin is widely
422 used, knowingly and as part of food products farmers are not necessarily aware of, in the
423 increasing mid-size farming industry(41). Another exciting new development are initial results
424 of combining fosfomycin and flomoxef(42); we observe only sporadic fosfomycin resistance
425 mechanisms and very little spread of *ampC* genes, the only non-carbapenemases that would
426 deactivate flomoxef, although we note that there are also counterindications for fosfomycin
427 use in invasive infections.

428

429 As extensively resistant bacterial pathogens emerge and spread, there is an increasing
430 urgency to develop vaccines to break the arms race between new antimicrobials and new
431 resistance mechanisms. In this case there is interest in developing maternally administered
432 *Klebsiella* vaccines to prevent neonatal sepsis. A target of high interest are the extracellular
433 polysaccharides that can be typed based on their respective operons, which are assigned
434 different K-types (capsular antigen) and O-types (the lipopolysaccharide O-antigen chain).
435 The K-antigen shows a very high diversity; and whilst we can identify several dominant types
436 in our study, the long timeframe of our study highlights the importance of considering the
437 dynamic nature of K-antigens when considering vaccine design. Here, temporal fluctuations
438 detected just in Blantyre strongly suggest that a K-type vaccine would become ineffective very
439 rapidly given the frequent changes in dominant K-type, which might be driven by phage
440 pressure in the environment and thus highly unpredictable. It is also unclear if successful
441 vaccination against the major polysaccharide types would lead to a degree of cross protection
442 against non-targeted types or whether lack of such cross protection would facilitate rapid
443 emergence of infections caused by vaccine escape lineages.

444

445 In contrast, there are far fewer O-antigen types, making this a more attractive target. Recent
446 efforts have compared several large datasets with O- and K-typing either determined by PCR
447 or WGS(43); and identified that a conjugate vaccine targeting O1v1/2 (~serotype O1)(31),
448 O2v2 (~serotype O2afg)(31) and O3b (~serotype O3b)(31) has the potential to prevent the
449 majority (>70%) of cases of *Kpn*-BSI. For the most at-risk population in our setting, the
450 neonates, this would cover 87% of cases (338/388) assuming O1a and O1b were included
451 into O1 and no other subtypes were discovered(30); importantly it would however not have
452 prevented the ST340 outbreak in the neonatal unit previously described(15) (O4). It thus

453 seems of relevance to consider including the currently low-abundance O-antigens as well, in
454 particular given the interchangeability for O-types within the same STs. Reports from other
455 highly understudied settings also report other main O-types in hospital isolates, e.g. O5 in a
456 study in Pakistan(17,44) or a diversity of O-types in the Caribbean where this O-Ag vaccine
457 would only cover 62% (162/260) (45). Selection pressure might not directly drive evolution
458 given that *Kpn* is not human restricted but could likely select for strains with currently less
459 abundant O-types to increase in prevalence. Further, there remains an open question of how
460 accessible the O-antigens are to antibodies, which a recent study calls into question(46); we
461 currently have very limited understanding what drives the extent of capsule expression per
462 cell in non-hypermucoid isolates and how different stages of the infection impact this. It is
463 known from *in vitro* studies that capsule expression even in the same experimental setting can
464 differ widely within clonal lineages, which also impacts the bacterial ability to escape the
465 complement system(47).

466

467 Our data, and the recent identification of a novel form of the long-studied O1 antigen
468 type(30,48–50), highlights that we have very little understanding of the relevance of the O-
469 and K-types on the success of *Kpn* lineages, whether any additional genes on the
470 chromosomal backbone can further modify the structures and lead to different serotypes with
471 the same O-locus, as well as whether any O-/K-combinations are more or less favourable.
472 Closing such knowledge gaps will be central to design of vaccines as we also have little
473 understanding for the propensity of sequence type combinations with specific vaccine target
474 serotypes such as capsule or O-antigen. A more solid understanding of O-/K-type variations,
475 both regarding their biochemistry and whether they contribute to epidemiological success, is
476 crucial given the high interest to use these as targets for maternally administered vaccines
477 against neonatal sepsis.

478

479 This highlights that we have very little understanding of the relevance of the O- and K-types
480 on the success of *Kpn* lineages, whether any additional genes on the chromosomal backbone
481 can further modify the structures and lead to different serotypes with the same o-locus, as well
482 as whether any O-/K-combinations are more or less favourable. A more solid understanding
483 of O-/K-type variations, both regarding their biochemistry and whether they contribute to
484 epidemiological success, is crucial given the high interest to use these as targets for
485 maternally administered vaccines against neonatal sepsis.

486

487 **Conclusions**

488 In summary, our study provides a unique insight into long-term patterns of *Kpn* hospital
489 isolates from a low-income setting, spanning across a time period where the number of MDR
490 and ESBL producing infections increased rapidly across the globe. We show that whilst STs
491 known as high-risk in other settings are common, these do not always show similar success
492 in different settings; and we observe a significant numbers of isolates from otherwise rarely
493 observed STs, causing hospital infections. This again emphasizes the importance of including
494 the relevant settings into studies aiming to identify treatment or vaccine targets as we currently
495 have poor understanding of what makes an ST a high-risk lineage in each setting at a given
496 time. Our data also emphasizes the urgent need to consider temporal variation when
497 considering treatment or vaccine targets, as some of the main vaccine targets show strong
498 temporal fluctuations; the most prevalent type now circulating is unlikely to cause the next
499 outbreak. The close relatedness of isolates from the same ward in the same time frame
500 strongly indicate that the majority of infections are hospital-acquired, so whilst vaccine

501 development and alternative treatment options are highly relevant; at this stage, focused
502 efforts to improve IPC are key to reducing *Kpn* disease burden now(21).

503

504 **Methods**

505 **Isolate collection**

506 QECH is a government run tertiary referral centre for the southern region of Malawi, which
507 provides free care at the point of delivery. It serves a population of 800,000 for the area of
508 urban Blantyre (Malawi census 2018). There are adult and paediatric A&Es, medical and
509 surgical wards. There is a tertiary neonatal unit on site and a separate paediatric surgical
510 hospital which opened in 2017 (Figure 2C; PICU, Paediatric HDU, Paediatric surgical ward).

511

512 **Microbiological sampling and processing**

513 Routine, (ISO15189 accredited since 2019) diagnostic blood culture services have been
514 provided to the medical and paediatric wards by the Malawi-Liverpool-Wellcome Programme
515 since 2000. For adults 7-10mL of blood were collected from all patients admitted to the hospital
516 with fever (axillary temperature $>37.5^{\circ}\text{C}$) or clinical suspicion of sepsis, severe sepsis, or
517 septic shock. Sepsis, severe sepsis, or septic shock were suspected in patients with
518 tachycardia (≥ 90 beats per minute), hypotension (systolic blood pressure < 90 mm Hg),
519 tachypnoea (respiratory rate > 20 per minute), or delirium. 3–10 mL of blood was taken from
520 children with non-focal febrile illness who tested negative for malaria, who were severely ill
521 with suspected sepsis, or who failed initial malaria treatment and remained febrile. For adults
522 and children with clinical suspicion of meningitis (temperature $> 37.5^{\circ}\text{C}$ with seizures,
523 headache, abnormal behaviour or meningism) a lumbar puncture was also performed and the
524 sample sent for CSF analysis. For neonates with clinical signs of sepsis or meningitis
525 (temperature $> 37.5^{\circ}\text{C}$, or other signs of clinical deterioration such as reduced activity,
526 increasing work of breathing or respiratory rate > 60 , heart rate > 180 or < 100 , and unexplained
527 seizures) a blood culture and CSF sample was collected. Afebrile patients were unlikely to
528 have had blood or CSF cultures unless the clinical suspicion for sepsis or meningitis was high.

529

530 For blood cultures, samples were collected using aseptic methods and inoculated into a single
531 aerobic bottle (BacT/Alert, bioMérieux, Marcy-L'Etoile, France). These were incubated using
532 the automated BacT/Alert system (bioMérieux, France) since 2000. Before which, they were
533 cultured manually. Samples that flagged positive were Gram stained and Gram-negative
534 bacilli are identified by Analytical Profile Index (Biomérieux). CSF samples were processed
535 for cell count and biochemistry before manual culture. Antimicrobial susceptibility testing was
536 determined by the disc diffusion method (Oxoid, United Kingdom) using AST breakpoints that
537 were current at the time, initially following the relevant version of the British Society of
538 Antimicrobial Chemotherapy's guidelines until 2018, after which time EUCAST methods and
539 breakpoints were introduced. Organisms which showed reduced inhibition when exposed to
540 Ceftriaxone 30mg discs, Ceftriaxone 5mg discs, or Cefpodoxime 10mg discs were classified
541 as resistant to Ceftriaxone. Intermediate isolates were classified as resistant to ceftriaxone.
542 Details for the identification of other organisms are described elsewhere(3). *Klebsiella*
543 *pneumoniae* isolates were stored at -80°C on microbank beads.

544

545 **Whole genome sequencing and QC**

546 All *Klebsiella pneumoniae* isolates that could be recovered from the start of the MLW archive
547 to April 2020 were thawed and incubated on MaConkey's media for 18-24 hours at 37°C .
548 Plates with pure growth then had a single colony pick taken and inoculated into 15 ml of

549 buffered peptone water for 18-24 hours at 37°C. These samples were then centrifuged and
550 the supernatant was discarded. The pellet was then resuspended in buffer and the DNA was
551 extracted using the QIA Symphony machine and QIA Symphony DSP kit with onboard lysis,
552 according to the manufacturer's instructions. Quality control was done using Qubit and
553 samples with a DNA volume of less than 200ng were repeated. DNA was sequenced at the
554 Wellcome Sanger Institute on the Illumina HiSeq X10 instrument (Illumina Inc., United States)
555 to produce 150 bp paired end reads.

556
557 Eleven out of 1313 samples failed the Sanger-internal sequencing threshold for minimum
558 coverage for assemblies and were thus removed from further analyses. Quality control on all
559 remaining isolates was performed using species confirmation via Kraken v0.10.6(51) to
560 identify contaminants (incorrect species). Any species assignment other than *Klebsiella*
561 *pneumoniae*, *Klebsiella variicola*, unclassified and synthetic construct were considered
562 contaminants; the latter two categories frequently derive from plasmid sequences in our
563 experience. All isolates with higher than 10% of other species were removed as contaminated
564 (Fig S2A). Similarly, isolates with a ratio of heterozygous SNPs over 5% were removed as
565 likely contaminated by a related strain (Fig S2B). Further quality control used the assemblies,
566 where all isolates resulting in more than 1000 contigs were removed as likely contaminated
567 by other species or strains, or of very low quality (Fig S2C). *De novo* assembly of the remaining
568 1156 genome sequences was performed using SPAdes v3.14.0(52) incorporated into the
569 bacterial genome assembly pipeline described previously(53). Annotation of all assemblies
570 was performed using prokka(54) v1.14.5.

571

572 **Genome analyses and phylogenetics**

573 For comparative analyses, isolates from recent studies at QECH were included, as they are
574 part of the bloodstream collection(14–16). Details of all sequences used in the analyses are
575 given in supplementary table 1. Resistance gene prediction and plasmid replicon types were
576 performed using arima(55) (v2.14.6) and the srst2-argannot(56,57), CARD(58) and
577 plasmidfinder(59) databases (download date 14.02.2022). To assess aminoglycoside
578 resistance; ANT3 is by arima as AacAad_AGly, AadA4_5_AGly, AadA_AGly, AadA_AGly_2,
579 AphA6_AGly; AAC(3)-II is grouped by arima as Aac3_Ila_AGly; ANT(2'')-I is grouped by arima
580 as AadB_AGly and AAC(6')-I is grouped by arima as AacAad_AGly_3.

581

582 Prediction of sequence types, (sub)species and *Klebsiella*-specific virulence factors were
583 performed using kleborate v2.1.0(60) and the `-r` setting; the results are given for all isolates
584 in Table S1. O- and K-types were predicted with kaptive(31) (v2.0.6) which incorporates O-
585 loci as well as O-serotype prediction(29,31,61); and we added an additional option of *wbbZ*
586 as extra gene to distinguish between O1a (O1/O2 + *wbbY*, no *wbbZ*) and O1b (O1/O2 + *wbbY*
587 + *wbbZ*) as described recently(30), adding *wbbZ* as implemented in kaptive versions before
588 v2(61) and expanding the .logic file to distinguish O1a/b.

589

590 Core genome SNPs for *K. pneumoniae* subsp. *pneumoniae* isolates were determined using
591 snippy(62) (v4.6.0; <https://github.com/tseemann/snippy>) with the *Klebsiella pneumoniae*
592 subsp. *pneumoniae* NTUH-K2044 genome (AP006725.1)(63) as reference. Recombinant
593 regions were removed using gubbins(64) (v3.2.1) and the FastTree(65) option ('-tree-builder
594 fasttree'), given the very high number of samples, as implemented in gubbins; and only
595 isolates from sequence types with more than one isolate in our dataset were included in the
596 analysis to further reduce compute time. The same strategy was used for *K. quasipneumoniae*

597 and *K. variicola* using strains ATCC 700603 (CP029597.1)(66) and At-22 (CP001891.1)(67)
598 as reference, respectively, where all isolates were included and default options for gubbins
599 were used (RaxML for tree generation, given the much smaller sample numbers). A snp-only
600 alignment was generated from the recombination-free gubbins output using snp-sites(68)
601 v2.5.1 with the -c option (selecting for ACGT-only) for *K. quasipneumoniae* and *K. variicola*;
602 for *K. pneumoniae* subsp. *pneumoniae*, given the high variation of isolates, the -c option was
603 too stringent (resulting in a <200 bp alignment) and we thus used snp-sites to isolate all snps
604 but without selecting for ACGT-only sites.

605
606 The snp-only alignments were used as input for iqtree(69) (v1.6.12), the number of constant
607 sites was determined with snp-sites -C function from the original full alignment and provided
608 to the '-fconst x,x,x,x' iqtree function. The model was determined with the integrated
609 ModelFinder(70) function '-m TEST' resulting in GTR+F+I+G4, GTR+F+I+G4, TVM+F+I+G4,
610 for the alignments from *K. pneumoniae*, *K. quasipneumoniae* and *K. variicola*, resp. We set '-
611 keep-ident' to keep identical data and '-bb 1000' for 1000 ultrafast bootstrap replicates. The
612 resulting trees were then adjusted to SNP-length branch lengths using the python
613 implementation of pyjar(71) (<https://github.com/simonrharris/pyjar>) as input for rPinecone(19).
614 Closely related clusters taking their phylogenetic distance into account were determined with
615 5 SNPs as cut-off for minor and 10 as cut-off for major clusters. These were visualised with
616 iTol(72) (v6.8) with visualisation files generated as implemented in rPinecone(19). For ST35,
617 ST39 and ST14/15 (combining ST14 and ST15 isolates in one analysis) we performed ST-
618 specific mappings of all respective isolates against references from these sequence types to
619 gain higher resolution (CP041353.2(73), LR991401.1(74) and CP008929.1(75), resp.).

620
621 Pan-genome reconstruction, generation of a core gene alignment, and identification of
622 neighbouring gene regions were derived via panaroo(76) (v1.3.3) using the '-clean-mode
623 strict' setting. The phylogenetic tree based on the core gene alignment, with informative sites
624 extracted with snp-sites as above, was calculated using iqtree(69) (v1.6.12) and the internal
625 ModelFinder(70) function (GTR+F+ASC+G4) as above. All other metadata summary analyses
626 and visualisation were generated using the ggplot(77) and ggtree(78) packages in R(79)
627 unless indicated otherwise; some colour schemes are derived from or inspired by the
628 MetBrewer (<https://github.com/BlakeRMills/MetBrewer>) and NationalParks
629 (<https://github.com/katiejolly/nationalparkcolors>) R libraries. Composite figures were
630 generated using the patchwork package (<https://github.com/thomasp85/patchwork>). An
631 RMarkdown file to generate the analysis plots and the underlying tree and data files are freely
632 available online (<https://github.com/EvitaH/QECHospitalKlebs>; doi:
633 10.5281/zenodo.8421658).

634
635

636 **Data availability**

637 All sequence data is available on SRA/ENA under BioProject PRJEB42462; specific
638 accessions and all additional data is provided in the supporting tables S1-S5. All data and
639 code used to create the analyses and is available as R package QECHospitalKlebs v0.0.9
640 (<https://github.com/EvitaH/QECHospitalKlebs>; doi: 10.5281/zenodo.8421658).

641

642 **Acknowledgments**

643 We would like to thank the Sanger Institute Pathogen Genomics group for expert
644 computational support. We acknowledge and thank all the clinical staff and patients at QECH

645 over the years for their contribution; and the MLW core microbiology team for expert support
646 in storage and handling of the isolates.

647

648 **Funding**

649 We acknowledge funding from Wellcome (EH; grant 217303/Z/19/Z) and the BMGF (NAF and
650 EH; grant INV-005180) as well as Wellcome funding providing core support for the Wellcome
651 Sanger Institute (206194) and MLW (206454). The funders had no role in study design, data
652 collection and analysis, decision to publish, or preparation of the manuscript.

653

654 **Ethics statement**

655 Ethical approval for this study was granted by the University of Malawi College of Medicine
656 Research Ethics Committee (COMREC) (P.11/18/2541) and isolates were shipped under a
657 Nagoya Protocol compliant Access and Benefit Sharing agreement between the Government
658 of Malawi and the Wellcome Sanger Institute.

659

660 **Competing interests**

661 The authors declare no competing interests.

662

663 **Author contributions**

664 Conceptualization: *EH, NAF*; Methodology: *EH, NAF*; Software: *EH, JML*; Validation: *EH, OP,*
665 *AZ*; Formal analysis: *EH, OP*; Investigation: *EH, OP, AZ, PM, PS, ET, FG, RL, SL, JC, JML*;
666 Resources: *SB, PS, ET, KK, NRT, NAF*; Data curation: *EH, OP, PM, RL, JC, JML, AZ*;
667 Writing—original draft: *EH, OP, NAF*; Writing—review & editing: *all authors*; Visualization: *EH,*
668 *OP, JML, NAF*; Supervision: *EH, CM, SL, KK, NAF*; Project administration: *EH, NAF*; Funding
669 acquisition: *EH, NRT, NAF*

670

671 **Figure legends:**

672 **Fig 1. *Kpn* cases at QECH. (A)** Numbers of *Kpn* cases per year at QECH. Bars represent the
673 crude frequency of *Kpn* infection for each year from 1998 - 2021, with the different colours
674 representing the different age groups of the patients. **(B)** Blood culture positivity rate (per 1,000
675 blood cultures) of *Kpn* in neonates and the entire patient population.

676 **Fig 2. Uneven distribution of STs and cases at QECH wards indicate hospital-acquired**
677 **infections. (A)** Main STs and **(B)** wards the samples were derived from over time. **(C)** A
678 schematic map of QECH with the wards samples of our study were derived from highlighted.
679 AETC – Adult emergency and Trauma Centre; Paediatric A&E – paediatric accident and
680 emergency; PICU – paediatric intensive care unit; HDU – high dependency unit.

681 **Fig 3. Most cases suspected to be caused by within-ward transmissions.** Mapping trees
682 against reference genomes for **(A)** *K. pneumoniae* subsp. *pneumoniae* excluding STs
683 represented with only a single isolate in the dataset, **(B)** *K. quasipneumoniae* and **(C)** *K.*
684 *variicola*. **(D-E)** show ST-specific mapping of the relevant isolates against references for ST35
685 **(D)**, ST39 **(E)**, ST14/ST15 **(F)**. The coloured tips indicates isolates with <5 SNPs distance to
686 their nearest neighbour based on a root-to-tip approach to identify related clusters of
687 isolates(19). The colour ring in **(A)** shows the main STs, the columns in **D-F** show year of
688 isolate (left column) and major ward (right column).

689 **Fig 4. Resistance mechanisms only explain beta-lactam, not aminoglycoside,**
690 **phenotypes. (A)** The distribution of ESBL genes over time illustrating the dominance of *bla*_{CTX-}
691 *M-15*. **(B)** Phenotypic chloramphenicol resistance profiles proportional over time and the
692 presence or absence of *catA1* and/or *catA2* compared to *catB4*, the recently re-characterised

693 non-functional CAT enzyme. **(C)** and **(D)** Predicted aminoglycoside resistance was based on
694 the presence of an Aac6'-Ib-cr or Aac6'-Ib gene (AAC(6')-I) for amikacin and Aac3_Ila
695 (AAC(3)-II) or AadB (ANT(2'')-I) for gentamicin. The x-axis shows the samples based on
696 phenotypic resistance profiles (intermediate, sensitive, resistant) against **(C)** amikacin and **(D)**
697 gentamicin, and the bars show number of isolates in the respective category that would have
698 been predicted as sensitive (blue) or resistant (red) based on the genes as above.

699 **Fig 5. High fluctuation of putative vaccine targets over time and diversity within major**
700 **STs.** The distribution of O-Ag locus types (top panels) and K-locus types (lower panels), resp.,
701 over time showing total numbers **(A)** and **(D)**, only isolates with ESBL resistance genes **(B)**
702 and **(E)** or ESBL-negative isolates **(C)** and **(F)**.

703

704 References

- 705 1. Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, et al. Global, regional, and national causes
706 of under-5 mortality in 2000-15: an updated systematic analysis with implications for the
707 Sustainable Development Goals. *Lancet Lond Engl.* 2016 Dec 17;388(10063):3027–35.
- 708 2. Sands K, Carvalho MJ, Portal E, Thomson K, Dyer C, Akpulu C, et al. Characterization of
709 antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low-
710 and middle-income countries. *Nat Microbiol.* 2021 Apr;6(4):512–23.
- 711 3. Musicha P, Cornick JE, Bar-Zeev N, French N, Masesa C, Denis B, et al. Trends in
712 antimicrobial resistance in bloodstream infection isolates at a large urban hospital in
713 Malawi (1998-2016): a surveillance study. *Lancet Infect Dis.* 2017;17(10):1042–52.
- 714 4. Salzberg NT, Sivalogan K, Bassat Q, Taylor AW, Adedini S, El Arifeen S, et al. Mortality
715 Surveillance Methods to Identify and Characterize Deaths in Child Health and Mortality
716 Prevention Surveillance Network Sites. *Clin Infect Dis.* 2019 Oct
717 9;69(Supplement_4):S262–73.
- 718 5. Wyres KL, Lam MMC, Holt KE. Population genomics of *Klebsiella pneumoniae*. *Nat Rev*
719 *Microbiol* [Internet]. 2020 Feb 13 [cited 2020 Feb 24]; Available from:
720 <http://www.nature.com/articles/s41579-019-0315-1>
- 721 6. Ellington MJ, Heinz E, Wailan AM, Dorman MJ, de Goffau M, Cain AK, et al. Contrasting
722 patterns of longitudinal population dynamics and antimicrobial resistance mechanisms in
723 two priority bacterial pathogens over 7 years in a single center. *Genome Biol.* 2019
724 02;20(1):184.
- 725 7. Lipworth S, Vihta KD, Chau K, Barker L, George S, Kavanagh J, et al. Ten-year
726 longitudinal molecular epidemiology study of *Escherichia coli* and *Klebsiella* species
727 bloodstream infections in Oxfordshire, UK. *Genome Med.* 2021 Sep 3;13(1):144.
- 728 8. Fostervold A, Hetland MAK, Bakksjø R, Bernhoff E, Holt KE, Samuelsen Ø, et al. A
729 nationwide genomic study of clinical *Klebsiella pneumoniae* in Norway 2001-15:
730 introduction and spread of ESBLs facilitated by clonal groups CG15 and CG307. *J*
731 *Antimicrob Chemother.* 2022 Feb 23;77(3):665–74.
- 732 9. Thorpe H, Booton R, Kallonen T, Gibbon MJ, Couto N, Passet V, et al. One Health or
733 Three? Transmission modelling of *Klebsiella* isolates reveals ecological barriers to
734 transmission between humans, animals and the environment [Internet]. *Microbiology*;
735 2021 Aug [cited 2023 May 17]. Available from:
736 <http://biorxiv.org/lookup/doi/10.1101/2021.08.05.455249>

- 737 10. Wyres KL, Nguyen TNT, Lam MMC, Judd LM, van Vinh Chau N, Dance DAB, et al.
738 Genomic surveillance for hypervirulence and multi-drug resistance in invasive *Klebsiella*
739 *pneumoniae* from South and Southeast Asia. *Genome Med.* 2020 Dec;12(1):11.
- 740 11. World Health Organization, editor. Antimicrobial resistance: global report on surveillance.
741 Geneva, Switzerland: World Health Organization; 2014. 232 p.
- 742 12. Rodrigues C, Passet V, Rakotondrasoa A, Diallo TA, Criscuolo A, Brisse S. Description
743 of *Klebsiella africanensis* sp. nov., *Klebsiella variicola* subsp. *tropicalensis* subsp. nov.
744 and *Klebsiella variicola* subsp. *variicola* subsp. nov. *Res Microbiol.* 2019
745 May;170(3):165–70.
- 746 13. Gordon MA, Walsh AL, Chaponda M, Soko D, Mbwinji M, Molyneux ME, et al.
747 Bacteraemia and mortality among adult medical admissions in Malawi--predominance of
748 non-typhi salmonellae and *Streptococcus pneumoniae*. *J Infect.* 2001 Jan;42(1):44–9.
- 749 14. Lester R, Musicha P, Kawaza K, Langton J, Mango J, Mangochi H, et al. Effect of
750 resistance to third-generation cephalosporins on morbidity and mortality from
751 bloodstream infections in Blantyre, Malawi: a prospective cohort study. *Lancet Microbe.*
752 2022 Dec;3(12):e922–30.
- 753 15. Cornick J, Musicha P, Peno C, Seager E, Iroh Tam PY, Bilima S, et al. Genomic
754 investigation of a suspected *Klebsiella pneumoniae* outbreak in a neonatal care unit in
755 sub-Saharan Africa. *Microb Genomics.* 2021 Nov;7(11).
- 756 16. Musicha P, Msefula CL, Mather AE, Chaguza C, Cain AK, Peno C, et al. Genomic
757 analysis of *Klebsiella pneumoniae* isolates from Malawi reveals acquisition of multiple
758 ESBL determinants across diverse lineages. *J Antimicrob Chemother.* 2019 May
759 1;74(5):1223–32.
- 760 17. Ejaz H, Wang N, Wilksch JJ, Page AJ, Cao H, Gujran S, et al. Phylogenetic Analysis of
761 *Klebsiella pneumoniae* from Hospitalized Children, Pakistan. *Emerg Infect Dis.* 2017
762 Nov;23(11):1872–5.
- 763 18. Chung The H, Karkey A, Pham Thanh D, Boinett CJ, Cain AK, Ellington M, et al. A high-
764 resolution genomic analysis of multidrug-resistant hospital outbreaks of *Klebsiella*
765 *pneumoniae*. *EMBO Mol Med.* 2015 Mar;7(3):227–39.
- 766 19. Wailan AM, Coll F, Heinz E, Tonkin-Hill G, Corander J, Feasey NA, et al. rPinecone:
767 Define sub-lineages of a clonal expansion via a phylogenetic tree. *Microb Genomics.*
768 2019;5(4).
- 769 20. Gorrie CL, Da Silva AG, Ingle DJ, Higgs C, Seemann T, Stinear TP, et al. Key
770 parameters for genomics-based real-time detection and tracking of multidrug-resistant
771 bacteria: a systematic analysis. *Lancet Microbe.* 2021 Nov;2(11):e575–83.
- 772 21. Mangochi H, Tolhurst R, Simpson V, Kawaza K, Chidziwisano K, Feasey NA, et al. A
773 qualitative study exploring hand hygiene practices in a neonatal unit in Blantyre, Malawi:
774 implications for controlling healthcare-associated infections. *Wellcome Open Res.*
775 2022;7:146.
- 776 22. Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, Morales IM, Palacios-Baena
777 ZR, Hernández-Torres A, et al. Effectiveness of Fosfomycin for the Treatment of
778 Multidrug-Resistant *Escherichia coli* Bacteremic Urinary Tract Infections: A Randomized
779 Clinical Trial. *JAMA Netw Open.* 2022 Jan 13;5(1):e2137277.

- 780 23. McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD. All-cause mortality
781 imbalance in the tigecycline phase 3 and 4 clinical trials. *Int J Antimicrob Agents*. 2013
782 May;41(5):463–7.
- 783 24. Veleba M, Schneiders T. Tigecycline Resistance Can Occur Independently of the *ramA*
784 Gene in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2012 Aug;56(8):4466–7.
- 785 25. Zhang R, Dong N, Huang Y, Zhou H, Xie M, Chan EWC, et al. Evolution of tigecycline-
786 and colistin-resistant CRKP (carbapenem-resistant *Klebsiella pneumoniae*) in vivo and
787 its persistence in the GI tract. *Emerg Microbes Infect*. 2018 Jul 9;7(1):127.
- 788 26. Roy S, Datta S, Viswanathan R, Singh AK, Basu S. Tigecycline susceptibility in
789 *Klebsiella pneumoniae* and *Escherichia coli* causing neonatal septicaemia (2007-10) and
790 role of an efflux pump in tigecycline non-susceptibility. *J Antimicrob Chemother*. 2013
791 May;68(5):1036–42.
- 792 27. He T, Wang R, Liu D, Walsh TR, Zhang R, Lv Y, et al. Emergence of plasmid-mediated
793 high-level tigecycline resistance genes in animals and humans. *Nat Microbiol*. 2019
794 Sep;4(9):1450–6.
- 795 28. Huang Y, Rana AP, Wenzler E, Ozer EA, Krapp F, Bulitta JB, et al. Aminoglycoside-
796 resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-
797 resistant *Klebsiella pneumoniae*. *J Antimicrob Chemother*. 2022 Feb 2;77(2):356–63.
- 798 29. Follador R, Heinz E, Wyres KL, Ellington MJ, Kowarik M, Holt KE, et al. The diversity of
799 *Klebsiella pneumoniae* surface polysaccharides. *Microb Genomics*. 2016;2(8):e000073.
- 800 30. Kelly SD, Ovchinnikova OG, Müller F, Steffen M, Braun M, Sweeney RP, et al.
801 Identification of a second glycoform of the clinically prevalent O1 antigen from *Klebsiella*
802 *pneumoniae*. *Proc Natl Acad Sci U S A*. 2023 Jul 18;120(29):e2301302120.
- 803 31. Lam MMC, Wick RR, Judd LM, Holt KE, Wyres KL. Kaptive 2.0: updated capsule and
804 lipopolysaccharide locus typing for the *Klebsiella pneumoniae* species complex. *Microb*
805 *Genomics* [Internet]. 2022 Mar 21 [cited 2023 Jul 20];8(3). Available from:
806 <https://www.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.000800>
- 807 32. Orskov I, Fife-Asbury MA. New *Klebsiella* Capsular Antigen, K82, and the Deletion of
808 Five of Those Previously Assigned. *Int J Syst Bacteriol*. 1977 Oct 1;27(4):386–7.
- 809 33. Edmunds PN. Further *Klebsiella* Capsule Types. *J Infect Dis*. 1954 Jan 1;94(1):65–71.
- 810 34. Edwards PR, Fife MA. Capsule Types of *Klebsiella*. *J Infect Dis*. 1952 Jul 1;91(1):92–
811 104.
- 812 35. Lewis JM, Mphasa M, Banda R, Beale MA, Heinz E, Mallewa J, et al. Colonization
813 dynamics of extended-spectrum beta-lactamase-producing Enterobacterales in the gut
814 of Malawian adults. *Nat Microbiol*. 2022 Oct;7(10):1593–604.
- 815 36. Lewis JM, Mphasa M, Banda R, Beale MA, Mallewa J, Heinz E, et al. Genomic and
816 antigenic diversity of colonizing *Klebsiella pneumoniae* isolates mirrors that of invasive
817 isolates in Blantyre, Malawi. *Microb Genomics*. 2022 Mar;8(3):000778.
- 818 37. Feasey NA, Houston A, Mukaka M, Komrower D, Mwalukomo T, Tenthani L, et al. A
819 Reduction in Adult Blood Stream Infection and Case Fatality at a Large African Hospital

- 820 following Antiretroviral Therapy Roll-Out. Pett S, editor. PLoS ONE. 2014 Mar
821 18;9(3):e92226.
- 822 38. Lewis JM, Lester R, Mphasa M, Banda R, Edwards T, Thomson NR, et al. Emergence of
823 carbapenemase-producing Enterobacteriaceae in Malawi. J Glob Antimicrob Resist.
824 2020 Mar;20:225–7.
- 825 39. Kumwenda GP, Sugawara Y, Abe R, Akeda Y, Kasambara W, Chizani K, et al. First
826 Identification and genomic characterization of multidrug-resistant carbapenemase-
827 producing Enterobacteriaceae clinical isolates in Malawi, Africa. J Med Microbiol. 2019
828 Dec 1;68(12):1707–15.
- 829 40. Zhang F, Li Q, Bai J, Ding M, Yan X, Wang G, et al. Heteroresistance to Amikacin in
830 Carbapenem-Resistant *Klebsiella pneumoniae* Strains. Front Microbiol. 2021;12:682239.
- 831 41. Mankhomwa J, Tolhurst R, M'biya E, Chikowe I, Banda P, Mussa J, et al. A Qualitative
832 Study of Antibiotic Use Practices in Intensive Small-Scale Farming in Urban and Peri-
833 Urban Blantyre, Malawi: Implications for Antimicrobial Resistance. Front Vet Sci. 2022
834 May 24;9:876513.
- 835 42. Darlow CA, Farrington N, Johnson A, McEntee L, Unsworth J, Jimenez-Valverde A, et
836 al. Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the
837 setting of highly prevalent antimicrobial resistance. J Antimicrob Chemother. 2022 Apr
838 27;77(5):1334–43.
- 839 43. Lipworth S, Vihta KD, Chau KK, Kavanagh J, Davies T, George S, et al. Ten Years of
840 Population-Level Genomic *Escherichia coli* and *Klebsiella pneumoniae* Serotype
841 Surveillance Informs Vaccine Development for Invasive Infections. Clin Infect Dis. 2021
842 Dec 16;73(12):2276–82.
- 843 44. Heinz E, Ejaz H, Bartholdson Scott J, Wang N, Gujran S, Pickard D, et al. Resistance
844 mechanisms and population structure of highly drug resistant *Klebsiella* in Pakistan
845 during the introduction of the carbapenemase NDM-1. Sci Rep. 2019 Dec;9(1):2392.
- 846 45. Heinz E, Brindle R, Morgan-McCalla A, Peters K, Thomson NR. Caribbean multi-centre
847 study of *Klebsiella pneumoniae*: whole-genome sequencing, antimicrobial resistance
848 and virulence factors. Microb Genomics [Internet]. 2019 May 1 [cited 2020 Feb 24];5(5).
849 Available from:
850 <https://www.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.000266>
- 851 46. Wantuch PL, Knoot CJ, Robinson LS, Vinogradov E, Scott NE, Harding CM, et al.
852 Capsular polysaccharide inhibits vaccine-induced O-antigen antibody binding and
853 function across both classical and hypervirulent K2:O1 strains of *Klebsiella pneumoniae*.
854 Hakansson AP, editor. PLOS Pathog. 2023 May 5;19(5):e1011367.
- 855 47. Loraine J, Heinz E, De Sousa Almeida J, Milevskyy O, Voravuthikunchai SP, Srimanote
856 P, et al. Complement Susceptibility in Relation to Genome Sequence of Recent
857 *Klebsiella pneumoniae* Isolates from Thai Hospitals. mSphere. 2018 07;3(6).
- 858 48. Kol O, Wieruszkeski JM, Strecker G, Fournet B, Zalisz R, Smets P. Structure of the O-
859 specific polysaccharide chain of *Klebsiella pneumoniae* O1K2 (NCTC 5055)
860 lipopolysaccharide. A complementary elucidation. Carbohydr Res. 1992 Dec
861 15;236:339–44.

- 862 49. Whitfield C, Richards JC, Perry MB, Clarke BR, MacLean LL. Expression of two
863 structurally distinct D-galactan O antigens in the lipopolysaccharide of *Klebsiella*
864 *pneumoniae* serotype O1. *J Bacteriol.* 1991 Feb;173(4):1420–31.
- 865 50. Kol O, Wieruszkeski JM, Strecker G, Montreuil J, Fournet B, Zalisz R, et al. Structure of
866 the O-specific polysaccharide chain from *Klebsiella pneumoniae* O1K2 (NCTC 5055)
867 lipopolysaccharide. *Carbohydr Res.* 1991 Sep 18;217:117–25.
- 868 51. Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using
869 exact alignments. *Genome Biol.* 2014 Mar 3;15(3):R46.
- 870 52. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a
871 new genome assembly algorithm and its applications to single-cell sequencing. *J*
872 *Comput Biol J Comput Mol Cell Biol.* 2012 May;19(5):455–77.
- 873 53. Page AJ, De Silva N, Hunt M, Quail MA, Parkhill J, Harris SR, et al. Robust high-
874 throughput prokaryote de novo assembly and improvement pipeline for Illumina data.
875 *Microb Genomics.* 2016;2(8):e000083.
- 876 54. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinforma Oxf Engl.* 2014
877 Jul 15;30(14):2068–9.
- 878 55. Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, Keane JA, et al. ARIBA: rapid
879 antimicrobial resistance genotyping directly from sequencing reads. *Microb Genomics.*
880 2017;3(10):e000131.
- 881 56. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, et al. SRST2: Rapid
882 genomic surveillance for public health and hospital microbiology labs. *Genome Med.*
883 2014;6(11):90.
- 884 57. Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, et al.
885 ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in
886 bacterial genomes. *Antimicrob Agents Chemother.* 2014;58(1):212–20.
- 887 58. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, et al. The
888 comprehensive antibiotic resistance database. *Antimicrob Agents Chemother.* 2013
889 Jul;57(7):3348–57.
- 890 59. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, et al. In
891 silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus
892 sequence typing. *Antimicrob Agents Chemother.* 2014 Jul;58(7):3895–903.
- 893 60. Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. A genomic
894 surveillance framework and genotyping tool for *Klebsiella pneumoniae* and its related
895 species complex. *Nat Commun.* 2021 Jul 7;12(1):4188.
- 896 61. Wick RR, Heinz E, Holt KE, Wyres KL. Kaptive Web: User-Friendly Capsule and
897 Lipopolysaccharide Serotype Prediction for *Klebsiella* Genomes. Diekema DJ, editor. *J*
898 *Clin Microbiol.* 2018 Apr 4;56(6):e00197-18, [/jcm/56/6/e00197-18.atom](https://doi.org/10.1128/JCM.56.6.e00197-18).
- 899 62. Torsten Seemann. snippy: fast bacterial variant calling from NGS reads [Internet].
900 Available from: <https://github.com/tseemann/snippy>

- 901 63. Wu KM, Li LH, Yan JJ, Tsao N, Liao TL, Tsai HC, et al. Genome sequencing and
902 comparative analysis of *Klebsiella pneumoniae* NTUH-K2044, a strain causing liver
903 abscess and meningitis. *J Bacteriol.* 2009 Jul;191(14):4492–501.
- 904 64. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, et al. Rapid
905 phylogenetic analysis of large samples of recombinant bacterial whole genome
906 sequences using Gubbins. *Nucleic Acids Res.* 2015 Feb 18;43(3):e15–e15.
- 907 65. Price MN, Dehal PS, Arkin AP. FastTree: Computing Large Minimum Evolution Trees
908 with Profiles instead of a Distance Matrix. *Mol Biol Evol.* 2009 Jul 1;26(7):1641–50.
- 909 66. Elliott AG, Ganesamoorthy D, Coin L, Cooper MA, Cao MD. Complete Genome
910 Sequence of *Klebsiella quasipneumoniae* subsp. *similipneumoniae* Strain ATCC
911 700603. *Genome Announc.* 2016 May 26;4(3):e00438-16.
- 912 67. Pinto-Tomás AA, Anderson MA, Suen G, Stevenson DM, Chu FST, Cleland WW, et al.
913 Symbiotic nitrogen fixation in the fungus gardens of leaf-cutter ants. *Science.* 2009 Nov
914 20;326(5956):1120–3.
- 915 68. Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T, Keane JA, et al. SNP-sites: rapid
916 efficient extraction of SNPs from multi-FASTA alignments. *Microb Genomics.*
917 2016;2(4):e000056.
- 918 69. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: A Fast and Effective
919 Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies. *Mol Biol Evol.*
920 2015 Jan;32(1):268–74.
- 921 70. Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermini LS. ModelFinder:
922 fast model selection for accurate phylogenetic estimates. *Nat Methods.* 2017
923 Jun;14(6):587–9.
- 924 71. Pupko T, Pe'er I, Shamir R, Graur D. A fast algorithm for joint reconstruction of ancestral
925 amino acid sequences. *Mol Biol Evol.* 2000 Jun;17(6):890–6.
- 926 72. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree
927 display and annotation. *Nucleic Acids Res.* 2021 Jul 2;49(W1):W293–6.
- 928 73. Shen Z, Gao Q, Qin J, Liu Y, Li M. Emergence of an NDM-5-Producing Hypervirulent
929 *Klebsiella pneumoniae* Sequence Type 35 Strain with Chromosomal Integration of an
930 Integrative and Conjugative Element, ICE *Kp1*. *Antimicrob Agents Chemother.* 2019 Dec
931 20;64(1):e01675-19.
- 932 74. Cabanel N, Rosinski-Chupin I, Chiarelli A, Botin T, Tato M, Canton R, et al. Evolution of
933 VIM-1-Producing *Klebsiella pneumoniae* Isolates from a Hospital Outbreak Reveals the
934 Genetic Bases of the Loss of the Urease-Positive Identification Character. Beiko RG,
935 editor. *mSystems.* 2021 Jun 29;6(3):e00244-21.
- 936 75. Stoesser N, Giess A, Batty EM, Sheppard AE, Walker AS, Wilson DJ, et al. Genome
937 sequencing of an extended series of NDM-producing *Klebsiella pneumoniae* isolates
938 from neonatal infections in a Nepali hospital characterizes the extent of community-
939 versus hospital-associated transmission in an endemic setting. *Antimicrob Agents*
940 *Chemother.* 2014 Dec;58(12):7347–57.

- 941 76. Tonkin-Hill G, MacAlasdair N, Ruis C, Weimann A, Horesh G, Lees JA, et al. Producing
942 polished prokaryotic pangenomes with the Panaroo pipeline. *Genome Biol.* 2020
943 Dec;21(1):180.
- 944 77. Wickham H. *Ggplot2: elegant graphics for data analysis*. New York: Springer; 2009. 212
945 p. (Use R!).
- 946 78. Yu G, Lam TTY, Zhu H, Guan Y. Two Methods for Mapping and Visualizing Associated
947 Data on Phylogeny Using Ggtree. *Mol Biol Evol.* 2018 01;35(12):3041–3.
- 948 79. R Core Team. *A Language and Environment for Statistical Computing* [Internet]. R
949 Foundation for Statistical Computing, Vienna.; 2021. Available from: [https://www.R-](https://www.R-project.org)
950 [project.org](https://www.R-project.org)
- 951








Figure 2

A) Sequence types over time



B) Wards over time



Main STs

- other
- ST101
- ST14
- ST15
- ST1552
- ST17
- ST25
- ST29
- ST307
- ST340
- ST35
- ST36
- ST37
- ST39
- ST391
- ST45
- ST48
- ST584
- ST607
- ST86

Major wards

- 3B MALE MEDICAL WARD
- 4A FEMALE MEDICAL WARD
- A ETC
- BURNS UNITS
- CHATINKHA NURSERY
- INTENSIVE CARE UNIT
- PAEDIATRIC A&E
- PAEDIATRIC MEDICAL BAY/WARD
- PAEDIATRIC MOYO WARD
- PAEDIATRIC NURSERY
- PAEDIATRIC ONCOLOGY
- PAEDIATRIC SPECIAL CARE WARD
- PAEDIATRIC SURGICAL WARD
- PICU/HDU
- unknown






Figure 3


A) *K. pneumoniae* subsp. *pneumoniae*




B) *K. quasipneumoniae*



C) *K. variicola*



D) ST35



E) ST39



F) ST14 & ST15






Figure 4

A) ESBL genes over time




B)

Phenotype vs chloramphenicol resistance genes



C) Phenotype vs predicted amikacin resistance



D)

Phenotype vs predicted gentamicin resistance

